ReviewBone marrow transplantation2010
Role of allo-SCT for CML in 2010.
Review in Bone marrow transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 18 citations in OpenAlex.
- Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.International journal of hematology · 2014Article
- Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.International journal of hematology · 2013Review
- Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience.Leukemia research reports · 2013Article
- Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors.Bone marrow transplantation · 2012Article
- Review
- Development of an effective therapy for chronic myelogenous leukemia.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML. However, for a minority of patients who fail TKI or progress to advanced phase disease, allo-SCT remains the only therapeutic option. This review addresses the current indications for allo-SCT in CML and the role of conditioning (myeloablative vs reduced intensity), donor source (sibling vs volunteer unrelated donor), graft source (BM vs peripheral blood vs cord) and the value of pre-, peri- and post transplant use of TKI in the management of CML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.